洛拉替尼
Tier B — Position earlyLorlatinib · all drugs expiring in 2030 →
Targets：ALK、ROS
Brand：Lorbrena、博瑞纳、Lorviqua
Indications (approved)：非小细胞肺癌
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| LORL-001 | 914225-70-0 | 1-(5-fluoro-2-iodophenyl)ethanone |
| LORL-002 | 1454847-96-1 | (S)-1-(5-fluoro-2-iodophenyl)ethanol |
| LORL-003 | 1454847-97-2 | (S)-1-(5-fluoro-2-iodophenyl)ethyl methanesulfonate |
| LORL-004 | 16867-03-1 | 2-aminopyridin-3-ol |
| LORL-005 | 1454847-98-3 | (R)-3-(1-(5-fluoro-2-iodophenyl)ethoxy)pyridin-2-amine |
| LORL-006 | 1454847-99-4 | (R)-methyl 2-(1-((2-aminopyridin-3-yl)oxy)ethyl)-4-fluorobenzoate |
| LORL-007 | 1454848-00-0 | (R)-methyl 2-(1-((2-amino-5-bromopyridin-3-yl)oxy)ethyl)-4-fluorobenzoate |
| LORL-008 | 1454848-24-8 | tert-butyl ((4-bromo-5-cyano-1-methyl-1H-pyrazol-3-yl)methyl)(methyl)carbamate |
| LORL-009 | - | (R)-methyl 2-(1-((2-amino-5-(3-(((tert-butoxycarbonyl)(methyl)amino)methyl)-5-cyano-1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)oxy)ethyl)-4-fluorobenzoate |
| LORL-010 | - | (R)-2-(1-((2-amino-5-(3-(((tert-butoxycarbonyl)(methyl)amino)methyl)-5-cyano-1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)oxy)ethyl)-4-fluorobenzoic acid |
| LORL-011 | 1454850-15-7 | (R)-2-(1-((2-amino-5-(5-cyano-1-methyl-3-((methylamino)methyl)-1H-pyrazol-4-yl)pyridin-3-yl)oxy)ethyl)-4-fluorobenzoic acid hydrochloride |
| Code | CAS No. | Intermediate |
|---|---|---|
| LORL-005 | 1454847-98-3 | (R)-3-(1-(5-fluoro-2-iodophenyl)ethoxy)pyridin-2-amine |
| LORL-008 | 1454848-24-8 | tert-butyl ((4-bromo-5-cyano-1-methyl-1H-pyrazol-3-yl)methyl)(methyl)carbamate |
| LORL-012 | 5775-89-3 | ethyl 4-bromo-1,3-dimethyl-1H-pyrazole-5-carboxylate |
| LORL-013 | 1454848-19-1 | ethyl 4-bromo-3-(bromomethyl)-1-methyl-1H-pyrazole-5-carboxylate |
| LORL-014 | 16066-84-5 | tert-butyl methylcarbamate |
| LORL-015 | 1454848-21-5 | ethyl 4-bromo-3-(((tert-butoxycarbonyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-5-carboxylate |
| LORL-016 | 1454848-22-6 | 4-bromo-3-(((tert-butoxycarbonyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-5-carboxylic acid |
| LORL-017 | 1454848-23-7 | tert-butyl ((4-bromo-5-carbamoyl-1-methyl-1H-pyrazol-3-yl)methyl)(methyl)carbamate |
| LORL-018 | 1454848-70-4 | tert-butyl ((5-cyano-1-methyl-1H-pyrazol-3-yl)methyl)(methyl)carbamate |
| LORL-019 | 1454852-76-6 | 1-methyl-3-((methylamino)methyl)-1H-pyrazole-5-carbonitrile |
| LORL-020 | 1612891-02-7 | (R)-2-(1-((2-aminopyridin-3-yl)oxy)ethyl)-N-((5-cyano-1-methyl-1H-pyrazol-3-yl)methyl)-4-fluoro-N-methylbenzamide |
| LORL-021 | 1612891-03-8 | (R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy)ethyl)-N-((5-cyano-1-methyl-1H-pyrazol-3-yl)methyl)-4-fluoro-N-methylbenzamide |
| LORL-022 | 1612891-04-9 | (R)-2-(1-((2-(N-acetylacetamido)-5-bromopyridin-3-yl)oxy)ethyl)-N-((5-cyano-1-methyl-1H-pyrazol-3-yl)methyl)-4-fluoro-N-methylbenzamide |
Frequently asked questions
What are the approved indications of Lorlatinib?
Approved indications include: 非小细胞肺癌.
When does the Lorlatinib patent expire?
Based on public sources, the Lorlatinib patent expires in 2030.
How many synthesis routes are recorded for Lorlatinib?
2 synthesis routes are recorded; the shortest is 9 steps with 110 mg total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Lorlatinib intermediates?
All intermediates in Lorlatinib routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Lorlatinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24